Zhenzhen Xu

Also affiliated with United States Food and Drug Administration, Wenzhou Medical University, First Affiliated Hospital of Wenzhou Medical University, Xuzhou Central Hospital, Food and Drug Administration

MathematicsMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 6 papers. Top paper: “FDA Approval Summary: Idecabtagene Vicleucel for Relapsed or Refractory Multiple Myeloma”.

FDA Approval Summary: Idecabtagene Vicleucel for Relapsed or Refractory Multiple Myeloma

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-3803

N/A

2.6DataRank · unranked

94 citations

Bindu Kanapuru, Bindu George, Xue Lin, Zhenzhen Xu, Wilson W. Bryan +3 more

Treating non-responders: pitfalls and implications for cancer immunotherapy trial design

Journal of Hematology & Oncology(2020)10.1186/s13045-020-0847-x

N/A

0DataRank · unranked

14 citations

Yongsoek Park, Ke Liu, Bin Zhu, Zhenzhen Xu

Design for immuno‐oncology clinical trials enrolling both responders and nonresponders

Statistics in Medicine(2020)10.1002/sim.8694

N/A

0DataRank · unranked

5 citations

Bin Zhu, Yongsoek Park, Zhenzhen Xu

FDA Approval Summary: Axicabtagene Ciloleucel for Second-Line Treatment of Large B-Cell Lymphoma

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-0568

N/A

0DataRank · unranked

24 citations

Yvette L. Kasamon, Xue Lin, Zhenzhen Xu, Marc R. Theoret, Tejashri Purohit-Sheth +1 more

FDA Approval Summary: Nadofaragene Firadenovec-vncg for Bacillus Calmette–Guérin–Unresponsive Non–Muscle-Invasive Bladder Cancer

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-2812

N/A

0DataRank · unranked

24 citations

Yuxia Jia, Anurag Sharma, Jiang Hu, Zhenzhen Xu, Daniel L. Suzman +5 more

FDA Approval Summary: Idecabtagene Vicleucel for the Treatment of Triple-Class–Exposed, Relapsed or Refractory Multiple Myeloma

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-24-4181

N/A

0DataRank · unranked

8 citations

Xue Lin, Zhenzhen Xu, Bindu Kanapuru, Marc R. Theoret, Robert Sokolic +2 more